Medicines Patent Pool/BMS Deal On Atazanavir To Benefit 110 Developing Countries, But Not China And Brazil
This article was originally published in PharmAsia News
Executive Summary
The Medicines Patent Pool’s deal with BMS for licenses for the manufacture and supply of atazanavir for low- to middle-income countries will benefit up to a million HIV sufferers.